We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

58 hedge funds and large institutions have $116M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 3

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

44% more capital invested

Capital invested by funds: $80.3M → $116M (+$35.5M)

35% more funds holding

Funds holding: 43 → 58 (+15)

Holders
58
Holders Change
+15
Holders Change %
+34.88%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
15
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$8.36M
2
GCL
Glazer Capital LLC
New York
+$4.8M
3
WAM
Weiss Asset Management
Massachusetts
+$4.24M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.65M
5
HIM
HGC Investment Management
Ontario, Canada
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
-$2.92M
2
SSA
Schonfeld Strategic Advisors
New York
-$1.24M
3
HighTower Advisors
HighTower Advisors
Illinois
-$240K
4
FTUS
Flow Traders U.S.
New York
-$230K
5
RA
Ramius Advisors
New York
-$168K
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$1.5M +$1M +4,069 +204%
KIM
27
Karpus Investment Management
New York
$1.34M – – –
AA
28
AQR Arbitrage
Connecticut
$1.33M +$1.33M +5,400 New
MP
29
Mangrove Partners
Connecticut
$1.25M +$257K +1,044 +26%
PMAM
30
Picton Mahoney Asset Management
Ontario, Canada
$990K +$984K +4,000 New
Alyeska Investment Group
31
Alyeska Investment Group
Illinois
$989K – – –
TCM
32
Tenor Capital Management
New York
$989K – – –
WA
33
Whitebox Advisors
Minnesota
$989K – – –
BCM
34
Basso Capital Management
Connecticut
$981K -$8.12K -33 -0.8%
ACM
35
Atalaya Capital Management
New York
$967K – – –
MIG
36
Mariner Investment Group
New York
$898K +$894K +3,633 New
LCM
37
Landscape Capital Management
New Jersey
$835K +$831K +3,378 New
EAM
38
Exos Asset Management
New York
$593K -$57.1K -232 -9%
BI
39
Bulldog Investors
New Jersey
$585K +$90.5K +368 +18%
LC
40
Littlejohn & Co
Connecticut
$495K +$492K +2,000 New
SCM
41
Segantii Capital Management
Hong Kong
$495K +$492K +2,000 New
PI
42
PEAK6 Investments
Illinois
$494K -$492 -2 -0.1%
WRBC
43
W.R. Berkley Corp
Connecticut
$492K – – –
WAM
44
Wolverine Asset Management
Illinois
$460K +$453K +1,840 +7,667%
NAM
45
Nexpoint Asset Management
Texas
$382K +$236K +960 +164%
Walleye Trading
46
Walleye Trading
New York
$296K +$295K +1,199 New
Jane Street
47
Jane Street
New York
$288K +$37.6K +153 +15%
Bank of America
48
Bank of America
North Carolina
$268K – – –
RCM
49
Rivernorth Capital Management
Florida
$247K – – –
AWG
50
Alpha Wave Global
New York
$242K +$240K +977 New
1
2
3

EFTR Hedge Fund Activity: Q2 2021 in Review

58 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2021, worth a combined $116M — up 44% from $80.3M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EFTR positions and 5 closed out — a net gain of 15 holders — while 15 added to existing stakes and 3 trimmed.

The largest buyer was Aristeia Capital, adding an estimated $8.36M. The largest seller was Blackstone Inc, exiting entirely with an estimated $2.92M sold.

  • 58 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2021, up from 43 in Q1 2021.
  • Funds reported $116M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2021, up 44% quarter-over-quarter.
  • 20 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2021 and 5 closed out, a net change of +15 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2021 was Aristeia Capital, an estimated $8.36M added.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2021 was Blackstone Inc, an estimated $2.92M sold.

Based on aggregated 13F filings for Q2 2021.